semaglutide and cagrilintide Cagrilintide–semaglutide (CagriSema) as an add-on to basal insulin in adults with type 2 diabetes (REIMAGINE 3): a randomised, double-blind, placebo-controlled, multicentre, phase 3 study Novo Nordisk has officially filed

High Satisfaction with GLP-1 Weight Loss Medications Satisfaction remains high, with 84% of current users and 77% of former users reporting positive results

inject once daily

One patient from the antioxidant group and 2 patients from the placebo group discontinued the intervention due to an unscheduled surgery

Demographic, clinical, and surgical data, including age, gender, pre-surgical BMI, type of surgery performed, baseline and nadir weight, comorbidities at baseline and during follow-up, as well as details of arGLP-1 (duration and dosing), were obtained

Over a maximum follow-up of 7.5 years, 173 total incident NAION events occurred

Back Molteni, M (17 Oct 2023) 'How one scientist's determination made Novo Nordisk an obesity-drug powerhouse', STAT News